[go: up one dir, main page]

IS6195A - Notkun á mótefnum gegn CD20 til meðhöndlunar á þegahöfnunarveiki - Google Patents

Notkun á mótefnum gegn CD20 til meðhöndlunar á þegahöfnunarveiki

Info

Publication number
IS6195A
IS6195A IS6195A IS6195A IS6195A IS 6195 A IS6195 A IS 6195A IS 6195 A IS6195 A IS 6195A IS 6195 A IS6195 A IS 6195A IS 6195 A IS6195 A IS 6195A
Authority
IS
Iceland
Prior art keywords
silencing
treatment
antibodies against
antibodies
Prior art date
Application number
IS6195A
Other languages
English (en)
Inventor
Golay Josee
Introna Martino
Rambaldi Alessandro
Biondi Andrea
Original Assignee
Consiglio Nazionale Delle Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Delle Ricerche filed Critical Consiglio Nazionale Delle Ricerche
Publication of IS6195A publication Critical patent/IS6195A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IS6195A 1999-06-11 2001-12-10 Notkun á mótefnum gegn CD20 til meðhöndlunar á þegahöfnunarveiki IS6195A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
PCT/EP2000/005212 WO2000076542A1 (en) 1999-06-11 2000-06-07 Use of antibodies against cd20 for the treatment of the graft versus host disease

Publications (1)

Publication Number Publication Date
IS6195A true IS6195A (is) 2001-12-10

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6195A IS6195A (is) 1999-06-11 2001-12-10 Notkun á mótefnum gegn CD20 til meðhöndlunar á þegahöfnunarveiki

Country Status (26)

Country Link
US (1) US20070014785A1 (is)
EP (1) EP1185299B1 (is)
JP (1) JP2003501482A (is)
KR (1) KR20020026455A (is)
CN (1) CN1253208C (is)
AU (1) AU774206B2 (is)
BG (1) BG106193A (is)
CA (1) CA2376288A1 (is)
CZ (1) CZ20014450A3 (is)
DE (1) DE60033030T2 (is)
DK (1) DK1185299T3 (is)
EE (1) EE200100667A (is)
ES (1) ES2278616T3 (is)
HK (1) HK1043549B (is)
HU (1) HUP0201600A3 (is)
IL (1) IL146934A0 (is)
IS (1) IS6195A (is)
IT (1) ITMI991299A1 (is)
NO (1) NO20016035L (is)
NZ (1) NZ515992A (is)
PL (1) PL352860A1 (is)
PT (1) PT1185299E (is)
SK (1) SK18132001A3 (is)
TR (1) TR200103581T2 (is)
WO (1) WO2000076542A1 (is)
ZA (1) ZA200110004B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
PT1631313E (pt) 2003-06-05 2015-07-02 Genentech Inc Terapêutica de combinação para distúrbios de células b
WO2005093079A1 (en) * 2004-03-22 2005-10-06 The Ohio State University Research Foundation Methods for transfecting natural killer cells
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
JP5403752B2 (ja) 2007-06-22 2014-01-29 北海道公立大学法人 札幌医科大学 移植片対宿主疾患の検査および治療方法
PL4365189T3 (pl) 2007-07-09 2025-05-26 F. Hoffmann-La Roche Ag Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów
AU2008282152B2 (en) 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
EP2233149B1 (en) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
SG189772A1 (en) 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3699198B1 (en) 2014-11-17 2025-03-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
CN114057885A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
DK3844189T3 (da) 2018-08-31 2025-02-24 Regeneron Pharma Doseringsstrategi, der mindsker cytokinfrigivelsessyndrom for CD3/CD20-bispecifikke antistoffer
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0977595A4 (en) * 1996-05-31 2001-05-16 Genetic Therapy Inc PREVENTION OF GAS REACTION AGAINST HOST USING THYMO-DEPENDENT LYMPHOCYTES CONTAINING POLYNUCLEOTIDES ENCODING NEGATIVE SELECTION MARKERS
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
CZ20014450A3 (cs) 2002-04-17
ES2278616T3 (es) 2007-08-16
TR200103581T2 (tr) 2002-08-21
NO20016035D0 (no) 2001-12-10
KR20020026455A (ko) 2002-04-10
NO20016035L (no) 2002-02-11
CN1253208C (zh) 2006-04-26
HUP0201600A2 (en) 2002-08-28
BG106193A (bg) 2002-08-30
SK18132001A3 (sk) 2002-05-09
PL352860A1 (en) 2003-09-08
WO2000076542A1 (en) 2000-12-21
DK1185299T3 (da) 2007-05-21
HUP0201600A3 (en) 2005-04-28
ITMI991299A1 (it) 2000-12-11
ITMI991299A0 (it) 1999-06-11
AU774206B2 (en) 2004-06-17
NZ515992A (en) 2004-01-30
US20070014785A1 (en) 2007-01-18
ZA200110004B (en) 2003-02-26
DE60033030T2 (de) 2007-05-31
EP1185299A1 (en) 2002-03-13
EE200100667A (et) 2003-02-17
AU5530300A (en) 2001-01-02
IL146934A0 (en) 2002-08-14
CA2376288A1 (en) 2000-12-21
HK1043549A1 (en) 2002-09-20
DE60033030D1 (de) 2007-03-08
HK1043549B (zh) 2006-09-01
PT1185299E (pt) 2007-03-30
EP1185299B1 (en) 2007-01-17
CN1355712A (zh) 2002-06-26
JP2003501482A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
IS6195A (is) Notkun á mótefnum gegn CD20 til meðhöndlunar á þegahöfnunarveiki
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
EP1071458A4 (en) HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF
IT1315260B1 (it) Bendaggio gastrico rimovibile
IS2468B (is) Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
IS2940B (is) Mótefni gegn CD40
NO20021526L (no) Anordning for kloakkbehandling
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
IS5982A (is) Aðferð til framleiðslu á 5-sýanóþalíði
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
NO20021964L (no) Biologisk fluidbehandling
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
IT1303677B1 (it) Dispositivo per il trattamento termico di pezzi.
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
IS3004B (is) Aðferð til meðhöndlunar á svefnleysi á frumstigi
NO20021670D0 (no) Anordning for behandling av fluider
FI20011550A0 (fi) Polypeptidien immobilisointimenetelmä
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer
NO20012616L (no) Middel til behandling av erektil malfunksjon